• Doxorubicin (Adriamycin): Applied Workflows in Cancer Cell R

  2026-04-30

  Doxorubicin (Adriamycin) remains a gold-standard chemotherapeutic and mechanistic probe for DNA damage and apoptosis induction in cancer models. This article bridges cutting-edge lipidomic insights with practical protocols, highlighting troubleshooting, advanced applications, and the unique value APExBIO brings to translational oncology workflows.

• EZ Cap™ Firefly Luciferase mRNA: Applied Workflows & Assay O

  2026-04-30

  EZ Cap™ Firefly Luciferase mRNA offers unparalleled stability and robust bioluminescent signaling, streamlining mRNA delivery and gene regulation assays. This article demystifies experimental setup, showcases advanced use-cases, and provides troubleshooting strategies to maximize assay sensitivity and reproducibility.

• CP-673451: Selective PDGFRα/β Inhibitor Redefining ATRX-Defi

  2026-04-29

  Explore how CP-673451, a selective PDGFRα/β inhibitor, is transforming cancer research by enabling precise angiogenesis inhibition and advanced modeling of ATRX-deficient glioma. This article offers unique protocol guidance and critical assay insights unavailable elsewhere.

• Cediranib (AZD2171): Advanced Assay Design for Angiogenesis

  2026-04-29

  Explore how Cediranib (AZD2171) enables precise, reproducible angiogenesis inhibitor assays in cancer research. This guide delivers new insights into in vitro drug response evaluation, assay decision-making, and the unique capabilities of Cediranib.

• Optimizing Cancer Research Workflows with LEE011 Succinate

  2026-04-28

  Ribociclib succinate (LEE011 succinate) stands out as a benchmark CDK inhibitor for advancing cell cycle and proliferation assays in cancer research. Through robust solubility, proven selectivity, and protocol-driven troubleshooting, it empowers labs to achieve reproducible, interpretable data when targeting cell cycle regulation.

• Nebivolol Hydrochloride: Precision in β1-Adrenoceptor Scienc

  2026-04-28

  This article offers translational researchers a mechanistic and strategic perspective on Nebivolol hydrochloride as a highly selective β1-adrenoceptor antagonist. It clarifies the biological rationale, experimental boundaries, and implications for cardiovascular pharmacology research, while distinguishing Nebivolol hydrochloride from mTOR pathway inhibitors and advancing best practices for reproducible β1-adrenergic receptor signaling research.

• Refining In Vitro Cancer Drug Evaluation: Insights from Schw

  2026-04-27

  Schwartz et al. introduce a nuanced framework for evaluating anti-cancer drug responses in vitro, distinguishing between proliferative arrest and cell death using relative and fractional viability metrics. This approach enables more precise interpretation of compound efficacy and informs improved experimental design in cancer research.

• BMN 673 (Talazoparib): Mechanistic Advances in PARP1/2 Inhib

  2026-04-27

  This thought-leadership article dissects the latest mechanistic discoveries in PARP1/2 inhibition, with a focus on BMN 673 (Talazoparib), and provides strategic guidance for translational researchers targeting homologous recombination-deficient cancers. Drawing on recent evidence, including the interplay between BRCA2, RAD51, and PARP1, the piece bridges foundational biology, experimental best practices, and clinical translation—while highlighting how APExBIO's BMN 673 enables next-generation research.

• Thrombin B Chain Fragment: Precision Control in Fibrin-Based

  2026-04-26

  Explore how the Coagulation Factor II (Thrombin) B Chain Fragment enables precise modulation of fibrinogen to fibrin conversion and platelet activation in advanced coagulation research. This article offers a unique, mechanistic perspective on thrombin’s role as a trypsin-like serine protease, with specialized insight into assay optimization and angiogenesis modeling.

• Remdesivir (GS-5734): Applied Workflows in Antiviral Researc

  2026-04-25

  Remdesivir (GS-5734) empowers virology labs with robust, reproducible inhibition of RNA viruses by directly targeting the viral RNA-dependent RNA polymerase. This guide translates structural insights and recent advances into actionable workflows, troubleshooting, and optimization for coronavirus and Ebola virus treatment research.

• Ibrexafungerp (MK 3118): Applied Antifungal Workflows & Insi

  2026-04-24

  Ibrexafungerp (MK 3118) stands out as a first-in-class oral triterpenoid antifungal, enabling robust experimental design against resistant Candida, including fluconazole- and echinocandin-resistant strains. This article translates cutting-edge findings into actionable workflows and troubleshooting strategies for both in vitro and in vivo models.

• Protease Inhibitor Cocktail EDTA-Free: Precision in Protein

  2026-04-24

  The Protease Inhibitor Cocktail EDTA-Free (100X in DMSO) offers robust, broad-spectrum protease inhibition without interfering with divalent cation-dependent assays. This ready-to-use solution preserves protein integrity during extraction and is especially valuable for workflows sensitive to phosphorylation status. Its stability and versatility make it a standard tool for advanced biochemical analyses.

• Anlotinib Hydrochloride: Redefining Anti-Angiogenic Assay De

  2026-04-23

  Explore the advanced scientific rationale and experimental design strategies enabled by Anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor. This article provides original, evidence-based guidance for optimizing angiogenesis and ERK signaling pathway inhibition assays.

• GPR30 in Spinal CCK+ Neurons: A Key Modulator of Neuropathic

  2026-04-23

  This study delineates the pivotal role of the G protein-coupled estrogen receptor GPR30 in spinal cholecystokinin-positive (CCK+) neurons as a driver of neuropathic pain. By using injury models and pathway-specific manipulations, the authors demonstrate that GPR30 upregulation in these neurons is essential for pain sensitization, highlighting a novel therapeutic target and providing mechanistic insight into central pain processing.

• CP-673451: Selective PDGFRα/β Inhibitor for Advanced Cancer

  2026-04-22

  CP-673451 enables nanomolar-precision inhibition of PDGFR signaling, supporting robust angiogenesis assays and tumor suppression studies, including in challenging ATRX-deficient glioma models. This guide delivers actionable workflows, troubleshooting strategies, and practical insights to maximize success with this selective PDGFRα/β inhibitor from APExBIO.

16272 records 1/1085 page Next 12345 下5页 Last page